dengue-fever

Documents about dengue-fever

• Prospective Study on the Risks of Dengue Fever for the Fetus.#911642ClinicalTrials.gov
• Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years#398189ClinicalTrials.gov
• Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study#825738ClinicalTrials.gov
• Diagnosis and Characterization of Dengue Fever in Children#833974ClinicalTrials.gov
• Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India#287366ClinicalTrials.gov
• Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia#880699ClinicalTrials.gov
• Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine#995447ClinicalTrials.gov
• The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever#907417ClinicalTrials.gov
• Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults#869995ClinicalTrials.gov
• Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock Syndrome#806272ClinicalTrials.gov
• Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America#867172ClinicalTrials.gov
• Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus#863324ClinicalTrials.gov
• Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine#876714ClinicalTrials.gov
• Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America#885496ClinicalTrials.gov
• Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule#910923ClinicalTrials.gov
• Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine#836537ClinicalTrials.gov
• Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou#894579ClinicalTrials.gov
• Gut Leakage' in Dengue#872554ClinicalTrials.gov
• Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age#67662ClinicalTrials.gov
• A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan#174941ClinicalTrials.gov
• A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)#880249ClinicalTrials.gov
• Hubungan Perilaku 3M Plus dengan Kejadian Demam Berdarah Dengue (DBD): 3M Plus Behavior with Event Dengue Hemorrhagic Fever (DHF)#1003877Jurnal Surya Medika (JSM)
• A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults#201605ClinicalTrials.gov
• Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients#895582ClinicalTrials.gov
• Study on the Risks of Symptomatic Dengue on Pregnancy#877996ClinicalTrials.gov
• Prospective Study of Infant Dengue#994311ClinicalTrials.gov
• Outbreak of dengue fever in Ghana: The emergence of DENV-1 serotype#172207PLOS
• Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue#283089ClinicalTrials.gov
• A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia#303561ClinicalTrials.gov
• Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection#911059ClinicalTrials.gov
• A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever#893024ClinicalTrials.gov
• International, but for whom? Pediatric sepsis guidelines and the limits of global applicability#358745PLOS
• Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms#833615ClinicalTrials.gov
• Epidemiology of dengue fever in Ethiopia: Insights from a systematic review and meta-analysis#624422Europe PMC
• Mosquito environmental DNA metabarcoding dataset in water-holding containers in dengue fever-endemic areas of DKI Jakarta, Indonesia#67581Europe PMC
• Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults#474801ClinicalTrials.gov
• International Research Consortium on Dengue Risk Assessment, Management, and Surveillance#826530ClinicalTrials.gov
• Incidence of Dengue Fever in Pakistan.#338510NCBI PubMed Central
• The global distribution and burden of dengue#7184OpenAlex
• Anti-dengue fever activity of a polyherbal extract from medicinal plants of Vietnam#425847S-Space: Seoul National University
• Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease#343689ClinicalTrials.gov
• Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease#683116ClinicalTrials.gov
• Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults#885194ClinicalTrials.gov
• Aplikasi Program Pencegahan DBD terhadap Perilaku Masyarakat dalam Pengawasan dan Pemberantasan Jentik Nyamuk Demam Berdarah Dengue dengan Menerapkan Teori Health Belief Model: Application of the Dengue Hemorrhagic Fever Prevention Program to the Behaviour of Community Support in Monitoring Larvae and Eradicating Dengue Hemorrhagic Fever Mosquite Larvae by Applying the Theory of Health Belief Models#1003849Jurnal Surya Medika (JSM)
• Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)#979889ClinicalTrials.gov
• Hubungan Pengetahuan dan Sikap dengan Perilaku Masyarakat tentang Pemberantasan Sarang Nyamuk Demam Berdarah Dengue (DBD): Correlation of Knowledge and Attitude with Community Behavior about the Eradication of Nests Mosquito Dengue Blood Fever (DHF)#1003911Jurnal Surya Medika (JSM)
• Bridging Economics and Public Trust: A Study of Dengue Vaccine Cost-effectiveness and Acceptance in Thais Visiting Hospital#848099ClinicalTrials.gov
• Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore#181588ClinicalTrials.gov
• Dengue and chikungunya interface in South and Southeast Asia: Epidemiology, challenges and future directions.#193909PubMed
• Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine#966151ClinicalTrials.gov